Featured Workshops
Novel Anticoagulants Workshop
Saturday, June 4
8:00 a.m.-Noon
Register at the SVM Registraiton Desk at the Meeting
Seaport Hotel, One Seaport Lane, Boston, Mass.
How these new medications, both in class and indication, fit appropriately into our armamentarium remains unclear. SVM has created this session to communicate the pharmacology, how the drugs should be used in venous thromboembolism and atrial fibrillation, the impact on hospital P&T committees and how the new agents will affect anticoagulation clinics.This is a stem-to-stern course on these new agents. This session presents speakers who are the leaders of the major clinical trials and nationally known experts in thrombosis.
This workshop is ideal for pharmacists, NPs, PAs, as well as physicians.
This workshop is included with your annual meeting registration or register for the workshop only for $75.
Workshop Program |
|
Pharmacology of the new agents |
TBA |
New Therapies in Atrial Fibrillation |
Jonathan Halperin, MD, FSVM, The Cardiovascular Institute |
New Directions in Venous Thromboembolism |
Samuel Z. Goldhaber, MD, FSVM, Brigham & Women's Hospital |
Case Discussions: (Panel of 3) |
Jerry Bartholomew, MD, FSVM, The Cleveland Clinic Foundation |
Impact of novel agents on a hospital's budget and anticoagulation service |
Julie K. Atay, PharmD, MBA, Brigham & Women's Hospital |
The P&T committee response to the $10/day pill, locally and nationally |
John Fanikos, PharmD, MBA, Brigham & Women's Hospital |
Panel discussion/audience Q & A |
Jerry Bartholomew, MD, FSVM, The Cleveland Clinic Foundation |
Accreditation for Pharmacists -- Novel Anticoagulant Workshop
TG Medical Education, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity provides 4 hours (0.4 CEUs) of continuing pharmacy education credit.
Antiplatelet Therapy Workshop
Friday, June 3,
10:20 a.m. - 11:20 a.m.
A targeted session on antiplatlet therapy will bring practitioners up to date. It will begin with a discussion of the biology of the platelet in atherosclerosis, whether patients with peripheral artery disease should be treated with aspirin, discuss whether genetic testing should be employed with antiplatlet agents, and bring everyone up to date in point-of-care platelet inhibition testing. These talks will be given by leaders in the field, a master class for cardiovascular physicians, NPs, and PAs in antiplatelet therapy in 2011.
This workshop is included with your annual meeting registration.
Workshop Program |
|
Inflammation and Platelets in Atherothrombosis |
Peter Libby, MD, Brigham & Women's Hospital |
Should PAD Patients Routinely Be Treated with Asprin? |
William R. Hiatt, MD, FSVM, CPC Clinical Research |
Genetics and Platelet Inhibition: |
Marc Sabatine, MD, MPH, Brigham & Women's Hospital |
Point of Care Platelet Reactivity Testing: 2011 |
Deepak Bhatt, MD, Brigham & Women's Hospital |